
Precipio PRPO
$ 28.82
4.8%
Quarterly report 2025-Q3
added 11-14-2025
Precipio Cash Conversion Cycle 2011-2026 | PRPO
Annual Cash Conversion Cycle Precipio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.19 | -36 | -42.3 | -46.8 | -153 | -600 | -1.11 K | -1.3 K | -644 | 63.6 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 63.6 | -1.3 K | -386 |
Quarterly Cash Conversion Cycle Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.7 | 17.2 | 16.8 | - | 13.8 | 11.1 | 18.2 | - | -40.9 | -51.6 | -35 | - | -43.8 | -62.6 | -46.5 | - | -36.7 | -58.3 | -58 | - | -49 | -46.8 | -75.1 | - | -145 | -152 | -374 | - | -590 | -630 | -566 | - | -1.05 K | -1.33 K | -1.41 K | - | -311 | -1.36 K | -831 | - | -692 | -678 | -704 | 34.7 | 104 | 63.9 | 85.1 | 78 | 96.8 | 89.5 | 129 | 101 | 161 | 142 | 147 | 80.6 | 114 | 127 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 161 | -1.41 K | -204 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M | ||
|
Bioventus
BVS
|
224 | $ 8.99 | 1.35 % | $ 599 M | ||
|
Castle Biosciences
CSTL
|
45.9 | $ 25.9 | 0.27 % | $ 719 M | ||
|
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
134 | $ 67.32 | 1.48 % | $ 26.3 B | ||
|
Guardant Health
GH
|
79.6 | $ 88.75 | 1.8 % | $ 11.1 B | ||
|
Charles River Laboratories International
CRL
|
65 | $ 153.71 | 1.14 % | $ 7.62 B | ||
|
CareDx, Inc
CDNA
|
51.5 | $ 17.6 | 1.62 % | $ 938 M | ||
|
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
42.5 | $ 103.94 | 0.09 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
42.4 | $ 15.43 | 3.21 % | $ 467 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
41.7 | $ 16.59 | -4.05 % | $ 2.15 B | ||
|
ICON Public Limited Company
ICLR
|
62 | $ 100.49 | 2.95 % | $ 8.29 B | ||
|
Anixa Biosciences
ANIX
|
275 | $ 2.89 | 1.76 % | $ 93.8 K | ||
|
IQVIA Holdings
IQV
|
73.9 | $ 168.43 | 2.15 % | $ 29 B | ||
|
Danaher Corporation
DHR
|
77.5 | $ 195.21 | 2.0 % | $ 139 B | ||
|
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | ||
|
Pacific Biosciences of California
PACB
|
185 | $ 1.38 | 1.47 % | $ 414 M | ||
|
Illumina
ILMN
|
142 | $ 120.84 | 1.31 % | $ 19.2 B | ||
|
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 198.61 | -0.17 % | $ 22 B | ||
|
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
111 | $ 112.75 | 0.82 % | $ 34.3 B | ||
|
BioNano Genomics
BNGO
|
225 | $ 1.13 | 1.8 % | $ 1.44 M | ||
|
DarioHealth Corp.
DRIO
|
207 | $ 8.75 | 3.92 % | $ 248 M | ||
|
NeoGenomics
NEO
|
82.4 | $ 8.27 | 0.36 % | $ 1.06 B | ||
|
Neogen Corporation
NEOG
|
150 | $ 9.27 | 1.76 % | $ 2.01 B | ||
|
Lantheus Holdings
LNTH
|
97.3 | $ 80.45 | 2.48 % | $ 5.43 B | ||
|
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
299 | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
50.4 | $ 455.15 | 0.33 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
66.4 | $ 1 206.72 | 0.63 % | $ 24.9 B | ||
|
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
29.4 | $ 17.73 | 1.9 % | $ 397 M | ||
|
Twist Bioscience Corporation
TWST
|
83.6 | $ 47.28 | 5.04 % | $ 2.83 B | ||
|
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
81.5 | $ 198.38 | 0.35 % | $ 19.5 B |